Skip to Main Content

Paper Details

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
EBioMedicine
48
2022
27, 27-gene expression, HER, HER2, HER2 amplicon, HER2-positive breast cancer, HER2-positive disease, HER2-positive tumours, HER2DX, early-, early-stage, gene expression, pCR, patients, tumour, tumour cell
Author NameAffiliation
Tomás Pascual
Joel S Parker
Joel S Parker
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina
  • 1 - 4

Datasets

Release 1.2